HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments.

6/1/2013

3 Comments

 
Sixty Percent of Surveyed Physicians Agree That They
Are Beginning To Warehouse HCV Patients Until New Interferon-Free Regimens Are
Available, According to a Recently Published BioTrends Report
     By BioTrends Research Group

BioTrends Research Group     
 
Last
modified: 2013-05-23T14:10:59Z

Published:
Thursday, May. 23, 2013 -  7:10 am
    Copyright 2013 . All rights
reserved. This material may not be published, broadcast, rewritten or
redistributed.


EXTON, Pa., May 23, 2013 -- /PRNewswire/ --
BioTrends Research Group, one of the world's leading research and advisory firms
for specialized biopharmaceutical issues, finds that, unaided, one in five
surveyed gastroenterologists, hepatologists, and infectious disease specialists
reported that in the past six months, they have begun warehousing patients
(e.g., intentionally delaying treatment) in anticipation of the next generation
of HCV treatments—notably more physicians than six months ago, when only 6
percent reported that they had begun warehousing patients.


(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO 
 


Furthermore, only one in five physicians agrees that they are satisfied with
currently available treatment options, underscoring the high unmet need for
alternatives to treat chronic HCV infections. The trending analyses of
physician-reported anticipated prescribing in TreatmentTrends®:
Hepatitis C Virus (US), Wave 1
also finds
that, for the first time in a year, surveyed physicians are expecting to treat a
greater proportion of their genotype 1 (3 percent) and 2/3 (3 percent) patients
in the next six months with regimens that are not currently available. Unaided
responses from most physicians who expect to be using other treatments suggest
they are expecting products in development, potentially interferon-free
regimens, to be available for use in the next six months.


In aided physician responses, Gilead's sofosbuvir and Janssen/Medivir's
simeprevir garnered the highest degree of familiarity for use in HCV treatment,
followed closely by Bristol-Myers Squibb's daclatasvir and asunaprevir.
Additionally, 20 percent of the surveyed physicians believe that Gilead's
sofosbuvir is the most promising product in development, primarily due to its
favorable tolerability, oral dosing, pan-genotypic activity, and its possibility
to be utilized as an interferon-free regimen.


"The protease inhibitors, Vertex's Incivek and Merck's Victrelis, were very
important advances in the management of HCV infections," said BioTrends Research
Group Associate Director, Lynn Price. "However, there is still a clear unmet
need for alternative HCV therapies and the recent NDA filings for simeprevir and
sofosbuvir have physicians hopeful for new treatment options that are highly
efficacious and more tolerable than the currently available protease
inhibitors."


TreatmentTrends®:
Hepatitis C Virus (US), Wave 1
is a report
that covers the use of agents for the treatment of HCV infections. This
bi-annual study focuses on current and future use of leading HCV treatment
regimens, patient market share, perceived strengths and weaknesses of the key
brands, barriers to broader usage, sales force performance, and perceived value
of manufacturers' patient assistance programs. In addition, this report assesses
potential impact of regimens in development, including Abbott's ABT-267,
ABT-333, and ABT-450, Boehringer Ingelheim's BI-207127 and faldaprevir,
Bristol-Myers Squibb's asunaprevir and daclatasvir, Janssen's simeprevir, and
Gilead's sofosbuvir and ledipasvir. In the current wave of research, BioTrends
surveyed 101 U.S. gastroenterologists, hepatologists, and infectious disease
specialists in March 2013.


About BioTrends Research Group BioTrends Research Group provides
syndicated and custom primary market research to pharmaceutical manufacturers
competing in clinically evolving, specialty pharmaceutical markets. For
information on BioTrends publications and research capabilities, please contact
us at www.bio-trends.com.
BioTrends is a Decision Resources Group company.


About Decision Resources Group Decision Resources Group is a cohesive
portfolio of companies that offers best-in-class, high-value information and
insights on important sectors of the healthcare industry. Clients rely on this
analysis and data to make informed decisions. Please visit Decision Resources
Group at www.DecisionResourcesGroup.com.


 
3 Comments
Clinical Trials GPS link
7/3/2013 08:01:25 am

I am looking forward to hearing more about these interferon-free medications that are being developed by the likes of Gilead Pharmaceuticals and Abbott Labs. I have read quite a bit about how harsh interferon injections can be for patients with hepatitis C. These next gen medications have produced very impressive results in clinical trials.

Reply
bestdissertations.com link
7/14/2013 08:56:11 pm

Your work is very good and I appreciate you and hopping for some more informative posts. Thank you for sharing great information to us.

Reply
tui xach thoi trang link
10/22/2013 05:01:07 pm

I like the valuable info you provide in your articles. I’ll bookmark your weblog and check again here regularly. I’m quite sure I’ll learn many new stuff right here! Good luck for the next!

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy